{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:02:46Z","timestamp":1778112166611,"version":"3.51.4"},"reference-count":21,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0743-5","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T16:02:32Z","timestamp":1573833752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Dual checkpoint inhibitor-associated eosinophilic enteritis"],"prefix":"10.1136","volume":"7","author":[{"given":"J.","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. M.","family":"Lagana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. M.","family":"Saenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3796-1118","authenticated-orcid":false,"given":"R. D.","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"743_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jaci.2003.10.047","volume":"113","author":"ME Rothenberg","year":"2004","unstructured":"Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol. 2004;113:11\u201328 quiz 9.","journal-title":"J Allergy Clin Immunol"},{"key":"743_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/modpathol.2010.221","volume":"24","author":"T Lwin","year":"2011","unstructured":"Lwin T, Melton SD, Genta RM. Eosinophilic gastritis: histopathological characterization and quantification of the normal gastric eosinophil content. Mod Pathol. 2011;24:556\u201363.","journal-title":"Mod Pathol"},{"key":"743_CR3","doi-asserted-by":"crossref","unstructured":"Pineton de Chambrun G, Dufour G, Tassy B, et al. Diagnosis, Natural History and Treatment of Eosinophilic Enteritis: a Review. Curr Gastroenterol Rep 2018;20:37.","DOI":"10.1007\/s11894-018-0645-6"},{"key":"743_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.gtc.2008.02.003","volume":"37","author":"S Khan","year":"2008","unstructured":"Khan S, Orenstein SR. Eosinophilic gastroenteritis. Gastroenterol Clin N Am. 2008;37:333\u201348 v.","journal-title":"Gastroenterol Clin N Am"},{"key":"743_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.bpg.2005.01.009","volume":"19","author":"S Khan","year":"2005","unstructured":"Khan S. Eosinophilic gastroenteritis. Best Pract Res Clin Gastroenterol. 2005;19:177\u201398.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"743_CR6","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.jaci.2014.07.026","volume":"134","author":"JM Caldwell","year":"2014","unstructured":"Caldwell JM, Collins MH, Stucke EM, et al. Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome. J Allergy Clin Immunol. 2014;134:1114\u201324.","journal-title":"J Allergy Clin Immunol"},{"key":"743_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/jgh.13463","volume":"32","author":"M Zhang","year":"2017","unstructured":"Zhang M, Li Y. Eosinophilic gastroenteritis: a state-of-the-art review. J Gastroenterol Hepatol. 2017;32:64\u201372.","journal-title":"J Gastroenterol Hepatol"},{"key":"743_CR8","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1084\/jem.185.9.1671","volume":"185","author":"S Tsuyuki","year":"1997","unstructured":"Tsuyuki S, Tsuyuki J, Einsle K, Kopf M, Coyle AJ. Costimulation through B7-2 (CD86) is required for the induction of a lung mucosal T helper cell 2 (TH2) immune response and altered airway responsiveness. J Exp Med. 1997;185:1671\u20139.","journal-title":"J Exp Med"},{"key":"743_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1365-2141.1990.tb07867.x","volume":"76","author":"D Macdonald","year":"1990","unstructured":"Macdonald D, Gordon AA, Kajitani H, Enokihara H, Barrett AJ. Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production. Br J Haematol. 1990;76:168\u201373.","journal-title":"Br J Haematol"},{"key":"743_CR10","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1182\/blood.V78.6.1538.1538","volume":"78","author":"PC Haelst van","year":"1991","unstructured":"van Haelst PC, Kovach JS, Kita H, et al. Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood. 1991;78:1538\u201344.","journal-title":"Blood"},{"key":"743_CR11","first-page":"805","volume":"1","author":"JA Sosman","year":"1995","unstructured":"Sosman JA, Bartemes K, Offord KP, et al. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clinical cancer research : an official journal of the American Association for Cancer Research. 1995;1:805\u201312.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"743_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejca.2017.05.017","volume":"81","author":"A Bernard-Tessier","year":"2017","unstructured":"Bernard-Tessier A, Jeanville P, Champiat S, et al. Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. Eur J Cancer. 2017;81:135\u20137.","journal-title":"Eur J Cancer"},{"key":"743_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053745","volume":"8","author":"CJ Voskens","year":"2013","unstructured":"Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8:e53745.","journal-title":"PLoS One"},{"key":"743_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/CMR.0000000000000326","volume":"27","author":"S Mirza","year":"2017","unstructured":"Mirza S, Hill E, Ludlow SP, Nanjappa S. Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome. Melanoma Res. 2017;27:271\u20133.","journal-title":"Melanoma Res"},{"key":"743_CR15","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"B Weide","year":"2016","unstructured":"Weide B, Martens A, Hassel JC, et al. Baseline biomarkers for outcome of melanoma patients treated with Pembrolizumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016;22:5487\u201396.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"743_CR16","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/cam4.1356","volume":"7","author":"S Rosner","year":"2018","unstructured":"Rosner S, Kwong E, Shoushtari AN, et al. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer medicine. 2018;7:690\u20137.","journal-title":"Cancer medicine"},{"issue":"15_suppl","key":"743_CR17","doi-asserted-by":"publisher","first-page":"9069","DOI":"10.1200\/jco.2015.33.15_suppl.9069","volume":"33","author":"Lydia Gaba","year":"2015","unstructured":"Gaba L, Victoria I, Pineda E. Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma. J Clin Oncol 2015;33, no. 15_suppl abstr 9069.","journal-title":"Journal of Clinical Oncology"},{"key":"743_CR18","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/annonc\/mdt027","volume":"24","author":"J Delyon","year":"2013","unstructured":"Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Annals of oncology : official journal of the European Society for Medical Oncology. 2013;24:1697\u2013703.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"key":"743_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s40800-018-0078-z","volume":"5","author":"M Occhipinti","year":"2018","unstructured":"Occhipinti M, Falcone R, Onesti CE, Marchetti P. Hyperprogressive disease and early Hypereosinophilia after anti-PD-1 treatment: a case report. Drug safety - case reports. 2018;5:12.","journal-title":"Drug safety - case reports"},{"key":"743_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/ni.3159","volume":"16","author":"R Carretero","year":"2015","unstructured":"Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hammerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015;16:609\u201317.","journal-title":"Nat Immunol"},{"key":"743_CR21","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.4049\/jimmunol.178.7.4222","volume":"178","author":"L Simson","year":"2007","unstructured":"Simson L, Ellyard JI, Dent LA, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol. 2007;178:4222\u20139.","journal-title":"J Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0743-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0743-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0743-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:45:52Z","timestamp":1601055952000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0743-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["743"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0743-5","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]},"assertion":[{"value":"26 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Columbia University requirements ( Policy.doc):Case report on a single patient: A case report describing the treatment of a single patient does not meet the federal definition of human subjects research on the basis that the information in the case report is not generalizable knowledge. Therefore, clinicians at the University are not required to obtain IRB approval for case reports of a single patient. Investigators who are asked by a journal or other entity to provide documentation from the IRB that such a case report was either approved by the IRB or did not require review by the IRB may present the Columbia Univesity IRB\/Privacy Board Policy on Case Reports as evidence that the case report does not require IRB approval.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RDC serves as a consultant to Array, BMS, Castle Biosciences, Compugen, Foundation Medicine, Immunocore, I-Mab, Incyte, Merck, Roche\/Genentech, PureTech Health, Sanofi Genzyme, and Sorrento Therapeutics. RC is also on the advisory board for Aura Biosciences, Chimeron, and Rgenix and receives research funding (to Columbia University) from Amgen, Astellis, AstraZeneca, Bayer, Bellicum, BMS, Corvus, Eli Lilly, Immunocore, Incyte, Macrogenics, Merck, Mirati, Novartis, Pfizer, Plexxikon, and Roche\/Genentech. YMS receives research and travel funding from Amgen. JY and SML declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"310"}}